BioCentury on BioBusiness,
Politics and Policy
SCOTUS-Myriad protects biotech patenting, but leaves important gray areas
The sky isn't falling
Monday, June 17, 2013
On balance, the biotech industry scored a net win in last week's
Supreme Court ruling in Association
for Molecular Pathology v. Myriad
Genetics Inc. that isolated DNA sequences cannot be patented. The bar
on patent claims for isolated DNA will have little practical effect, and any
immediate downside is outweighed by the benefits of pushing aside a contentious
issue that has tainted public perceptions of the industry and had the potential
to inhibit basic scientific research.
The decision instantly provided
patients access to cheaper breast cancer 1 early onset (BRCA1) and BRCA2 tests,
gave academic scientists more freedom to operate, and immunized biotech
companies from claims that they are trying to "own" the DNA that is
present in every cell in every human.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]